Sempra (SRE) concluded trading on Thursday at a closing price of $66.90, with 6.0 million shares of worth about $401.4 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -18.02% during that period and on April 10, 2025 the price saw a loss of about -1.70%. Currently the company’s common shares owned by public are about 651.91M shares, out of which, 651.46M shares are available for trading.
Stock saw a price change of -5.41% in past 5 days and over the past one month there was a price change of -2.97%. Year-to-date (YTD), SRE shares are showing a performance of -23.73% which decreased to -6.67% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $61.90 but also hit the highest price of $95.77 during that period. The average intraday trading volume for Sempra shares is 5.75 million. The stock is currently trading -3.57% below its 20-day simple moving average (SMA20), while that difference is down -10.22% for SMA50 and it goes to -17.62% lower than SMA200.
Sempra (NYSE: SRE) currently have 651.91M outstanding shares and institutions hold larger chunk of about 91.22% of that.
The stock has a current market capitalization of $43.61B and its 3Y-monthly beta is at 0.66. PE ratio of stock for trailing 12 months is 15.14, while it has posted earnings per share of $4.42 in the same period. Its PEG reads 2.89 and has Quick Ratio of 0.49 while making debt-to-equity ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SRE, volatility over the week remained 7.00% while standing at 3.33% over the month.
Stock’s fiscal year EPS is expected to drop by -2.01% while it is estimated to increase by 10.30% in next year. EPS is likely to grow at an annualized rate of 5.24% for next 5-years, compared to annual growth of 3.92% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on April 09, 2025 offering a Neutral rating for the stock and assigned a target price range of between $93 and $70 to it. On March 03, 2025, Jefferies Downgrade their recommendations, while on February 27, 2025, Barclays Downgrade their ratings for the stock with a price target of $72. Stock get a Neutral rating from UBS on February 26, 2025.
